American Family Life Assurance Co. v. Commissioner of InsuranceAmerican Family Life Assurance Co. v. Commissioner of Insurance
The defendant, the Commissioner of Insurance (Commissioner), appeals from two Superior Court judgments invalidating regulations promulgated by the Commissioner. The regulations, codified at 211 Code Mass. Regs. 47.07 (1) (a)-(e) and 47.09 (4) (a)-(c) (1980), effectively banned the sale of individual health insurance policies covering only one or a few diseases (specified disease insurance), unless they covered twelve listed diseases and met certain other requirements. The regulations were intended to curb abuses relating to the sale of cancer-risk insurance, which the Commissioner found was a poor health care investment, and was being marketed in an unscrupulous manner. The plaintiffs, American Family Life Assurance Company (American), and Union Fidelity Life Insurance Company (Union), had been selling cancer-risk insurance. They challenged the validity of the regulations in the Superior Court pursuant to
The judge found the following facts. Under prior regulations, American and Union had been selling cancer-risk insurance policies which had been approved by the Commissioner pursuant to standard procedures for the approval of
The regulations apply to “all individual . . . sickness insurance policies . . . filed with the Division of Insurance, delivered, or issued for delivery after the effective dates of this regulation .... No policy . . . covered by this regulation shall be issued or issued for delivery unless it complies with this regulation.” 211 Code Mass. Regs. 47.02 (1980). The regulations were to be effective upon publication, which occurred on September 27,1979. The Commissioner does not contend that the regulations apply to policies which were issued before that date. However, because there is no saving clause in the regulations, the Commissioner has deemed the regulations to apply to new sales of previously approved specified disease policies. Thus, under the regulations, American’s and Union’s previously approved cancer-risk insurance policies cannot be issued to new purchasers.
We are presented with three questions on this appeal. First, did the Commissioner have statutory authority to promulgate regulations 47.07 (1) (a)-(e) and 47.09 (4) (a)-(c) under
1. We first consider the scope of the Commissioner’s authority under
The plaintiffs argue that the phrase “full and fair disclosure, for the form and content of policies,” limits the Commissioner’s authority to the issuance of regulations aimed at ensuring full and fair disclosure. They rely chiefly on the use of the word “for,” and on the legislative history of
Although the plaintiffs’ interpretation of this portion of the statute is not unreasonable, the Commissioner advances an alternative view. He suggests that since the words “for the form and content of policies” are separated from the words “to establish minimum standards of full and fair disclosure” by a comma, each phrase “was intended to be a parallel and independent source of regulatory authority.” Thus, the Commissioner is empowered to make regulations concerning the content of insurance policies, consistent with the listed statutory goals, unrelated to disclosure.
We agree with the Commissioner’s interpretation, primarily because the plaintiffs’ construction is at odds with a workable reading of the entire statute. “Where the draftsmanship of a statute is faulty or lacks precision, it is our duty to give the statute a reasonable construction.”
School Comm. of Greenfield
v.
Greenfield Educ. Ass'n,
The Commissioner notes that the act which created
Moreover, the Commissioner’s contemporaneous, long-continued construction of
We conclude that
2. The judge found that regulations 47.07 (1) (a) and (d) were arbitrary and capricious. The judge considered the relationship between the regulations and
As a threshold matter, we note that there appears to be some confusion among the parties as to the difference between a challenge to a regulation in practice and on its face, and the proper standard of our review of the Superior Court judgment. The plaintiffs argue that because they produced evidence at trial, they attacked regulations 47.07 (1) (a) and (d) as arbitrary and capricious in practice, and we should review the judge’s decision under the “clearly erroneous” standard. If the regulations exceeded the Commissioner’s statutory authority, then they would be arbitrary and capricious on their face in that they would by definition be unrelated to the achievement of any statutory goals. Here the judge found that, even assuming the Commissioner was empowered to promulgate the regulations, they were not rationally related to the goals of
We have concluded that
Applying these principles to the instant case, we conclude that the plaintiffs did not carry their burden. The Commissioner’s opinion indicates that the twelve-disease requirement of regulation 47.07 (1) (a) was intended to curb abuses in the sale of cancer-risk insurance, including sales tactics exploiting public fear of the disease, and poor health care value. There was ample testimony before the Commissioner documenting these abuses. The Commissioner might well have determined that these abuses would be likely to occur in the sale of any specified disease insurance policy. It was, therefore, rational for him to take steps to eliminate the sale of insurance policies covering only one or a few diseases. Similarly, in light of evidence establishing the poor health care value of specified disease insurance, it was reasonable for him to prohibit the sale of such policies alone, by requiring in regulation 47.07 (1) (d) that they be sold only as a supplement to basic hospital insurance. 6
The plaintiffs’ evidence at most established that there was a difference of opinion among medical and insurance experts as to the utility of specified disease insurance, and the practicality and reasonableness of the requirements of regulations 47.07 (1) (a) and (d). Their evidence did not establish that the regulations lacked any conceivable basis. The plaintiffs did not even address the Commissioner’s conclusion that regulation 47.07 (1) (a) was necessary to curb marketing abuses in the sale of cancer insurance. We also note that in invalidating regulation 47.07 (1) (d), the judge relied on evidence that the regulation would make specified disease insurance difficult to market, so that “[f]or all practical purposes, the free-standing specified disease policy will be a thing of the past.” This was not relevant to show that regulation 47.07 (1) (d) lacked a rational basis, but rather amounted to a disagreement by the judge with the Commissioner’s judgment that such policies were detrimental to the public’s health care needs.
As we have emphasized, judicial review of regulations should not become a de nova trial in which the trial judge decides whether a challenged regulation is reasonable based on the evidence presented. Absent some other illegality, the scope of review is limited to the question whether the plain
We conclude that regulations 47.07 (1) (a) and (d) are not arbitrary and capricious. In light of the foregoing, we need not address the Commissioner’s other objections to the conduct of the trial.
3. Finally, we consider the judge’s ruling that the Commissioner could not withdraw his approval of new sales of American’s and Union’s previously approved cancer-risk insurance policies without an adjudicatory hearing. We emphasize that the disputed regulations do not attempt to rescind policies already sold, but merely withdraw approval of future sales to new purchasers of previously approved policies.
7
The plaintiffs base their argument on the reference to
Apart from the plain language of
Nor do constitutional principles require an adjudicatory hearing in these circumstances. The plaintiffs’ interest is in future sales to new purchasers of previously approved policies. This is not a property interest the deprivation of which requires a hearing to satisfy due process. See
Prong
horn,
Inc.
v.
Licensing Bd. of Peabody,
The judgments are reversed and judgments shall be entered declaring that the regulations here in issue are valid.
So ordered.
Notes
The judge found that all parties agreed that these regulations were developed through a rule making proceeding.
The regulations state that they are promulgated under the authority of
Because, as will be seen, we discern sufficient authority of the Commissioner in
The plaintiffs’ only claim that regulation 47.07 (1) (a) was illegal in practice was based on the disapproval of a chemotherapy rider submitted by the Physicians Mutual Insurance Co., which is not a party to this action. The plaintiffs lack standing to raise this issue. In any event, if the disapproval was illegal, the remedy would be to order approval of the rider, not to invalidate the regulation. See
Massachusetts State Pharmaceutical Ass’n
v.
Rate Setting Comm’n,
We note that we are, of course, free to consider the evidence before the Commissioner, as well as any other relevant information, including that provided in the briefs, in determining whether there was a rational basis for the Commissioner’s regulations.
Massachusetts State Pharmaceutical Ass'n
v.
Rate Setting Comm’n, 387
Mass. 122, 126 (1982), and
Grocery Mfrs. of Am., Inc.,
v.
Department of Pub. Health,
In his brief, the Commissioner noted that “[ejxisting insurance contracts remained in force and renewals of such existing contracts were not prohibited by . . . any . . . regulation.”
On this procedural ground, Union also objected to portions of the regulations governing Medicare supplement insurance.
In light of our holding, we do not address the Commissioner’s claim that the so called readability statute,